Use of Glucagon-like peptide 2 (GLP-2) analogs in inflammatory bowel disease

• Egile Nagusiak: Dobromiła Osuch (Egilea), Piotr Zatyka (Egilea), Adam Słomczyński (Egilea), Agata Pawłowska (Egilea), Michal Rabenda (Egilea), Piotr Janik (Egilea), Dominika Opala (Egilea)
• Formatua: Liburua
• Argitaratua: Nicolaus Copernicus University in Toruń, 2024-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Inflammatory bowel disease (IBD) is a chronic condition that involves long-term treatment and chronic idiopathic inflammation within the gastrointestinal tract. The predominant forms of IBD are: Crohn's disease and ulcerative colitis. These diseases cause significant physical as w...